Difference between revisions of "Ivosidenib (Tibsovo)"
Jump to navigation
Jump to search
m |
|||
| Line 4: | Line 4: | ||
==Diseases for which it is used== | ==Diseases for which it is used== | ||
*[[Acute_myeloid_leukemia,_IDH-mutated|IDH1-mutated AML]] | *[[Acute_myeloid_leukemia,_IDH-mutated|IDH1-mutated AML]] | ||
| + | *[[Cholangiocarcinoma]] | ||
==Patient drug information== | ==Patient drug information== | ||
| Line 27: | Line 28: | ||
[[Category:Acute myeloid leukemia medications]] | [[Category:Acute myeloid leukemia medications]] | ||
| + | [[Category:Cholangiocarcinoma medications]] | ||
[[Category:FDA approved in 2018]] | [[Category:FDA approved in 2018]] | ||
Revision as of 20:48, 15 June 2021
General information
Class/mechanism: IDH1 inhibitor. Ivosidenib inhibits the mutant isocitrate dehydrogenase 1 (IDH1) enzyme at lower drug concentrations than wild-type IDH1. Inhibiting mutant IDH1 enzyme prevents formation of the oncometabolite 2-hydroxyglutarate (2HG) in leukemia cells, causes a reduction in IDH1-expressing tumor cells, and increases percentages of mature myeloid cells.[1][2][3]
Diseases for which it is used
Patient drug information
History of changes in FDA indication
- 7/20/2018: Granted approval for adult patients with relapsed or refractory acute myeloid leukemia (AML) with a susceptible IDH1 mutation as detected by an FDA-approved test. (Based on AG120-C-001)
- 5/2/2019: FDA approval expanded "for newly-diagnosed acute myeloid leukemia (AML) with a susceptible IDH1 mutation, as detected by an FDA-approved test, in patients who are at least 75 years old or who have comorbidities that preclude the use of intensive induction chemotherapy." (approval expanded to first-line setting with limitations; based on AG120-C-001)
Also known as
- Code name: AG-120
- Brand name: Tibsovo